Immune-mediated inflammatory diseases (IMIDs) are a heterogeneous group of common, debilitating, yet publicly underappreciated chronic conditions, most of them primarily affecting women. They are mechanistically characterized by a breakdown in self-tolerance with no curative treatment presently at hand. With over 20 and 40 million Americans and Europeans affected respectively, they represent the third most common category of diseases after cancer and cardiovascular disorders. Multiple sclerosis (MS) is one of these chronic autoimmune diseases attacking the central nervous system (CNS) and affecting ~ 2.3 million people worldwide. To date, there is no cure for MS, but several immunomodulatory and immunosuppressive treatments are available and being developed to control disease activity, delay or even prevent disease progression, and improve quality of life. Yet, the variability in MS presentation and evolution together with the differences in efficacy and risk of treatments for MS is fostering the personalization of patient care to optimize the benefit-to-risk ratio for individual patients. Besides MS, precision medicine can also be applied to other common autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Systemic Sclerodermia (SS), Rheumatoid Arthritis (RA) or primary Sjögren’s disease (pSS), as well as to hematologic pathologies such as neutropenia. For all these pathologies, common tools and data analysis methodologies are needed.
Workshop language will be English.